Radioisotope developer MDS Nordion of Kanata, Ontario, is investing $5.8 million (U.S.) to expand its production facility in Fleurus, Belgium, to meet the demand for the imaging agent fluorine-18 fluorodeoxyglucose (F-18 FDG).
MDS Nordion markets FDG under the name Glucotrace, with production as part of a joint venture with the University of Liège in Belgium.
First production of Glucotrace from the new facility is expected to begin in mid-2008. The firm plans to serve more customers in France, Belgium, the Netherlands, and Luxembourg with its increased production.
By AuntMinnie.com staff writers
March 22, 2007
Related Reading
MDS names Prince as CFO, February 20, 2007
MDS Nordion opens European TheraSphere centers, February 8, 2007
MDS Nordion shows Q4 revenue downturn, year-end upturn, December 14, 2006
MDS sells diagnostics unit, October 5, 2006
MDS Nordion gets FDA OK for TheraSphere clinical trials, September 26, 2006
Copyright © 2007 AuntMinnie.com
